Protein & Peptides
CJC-1295 DAC 2mg vial
CJC-1295 DAC profile:
CJC-1295 peptide, is derived from human growth releasing factor hGRF(1-29). CJC-1295 peptide is a synthetic human GHRH analogue with drug affinity complex (DAC). This enables CJC-1295 peptide to be bound with albumin in the human body and significantly extend the half-life, by avoiding enzymatic degradation. CJC-1295 peptide DAC has an advantage over regular growth hormone releasing factors hGRF's to promote effects for extended periods of time, whereas regular hGRF can only act for minutes before it is degraded by enzymes CJC-1295 peptide is modified of hGRF with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively and drug affinity complex attached. These CJC-1295 peptide modifications results in much more stable and effective version of hGRF.
Studies report HGH increase by 2 to 10 times the normal levels when CJC-1295 peptide is applied. This consequently increases IGF-1 levels by 1.5 to 3 times within 9 days of a single injection. IGF-1 levels remained above normal levels for 28 days following the injection. No serious side effects were reported by study subjects CJC-1295 peptide was concluded to be very effective HGH stimulant.
3.2 kDa peptide containing 29 amino acid residues.
CJC-1295 DAC, Modified GRF 1-29 with DAC
Sterile Filtered White lyophilized (freeze-dried) powder.
>99.8% (HPLC analyzed).
Add 1 ml of sterile diluent and let the lyophilized pellet dissolve completely.
Store lyophilized peptide at -20 °C. Reconstituted peptide can be stored at 4 °C for a limited period of time. The lyophilized peptide remains stable until the expiry date when stored at -20 °C(48 Months)
The Product is prepared for LABORATORY RESEARCH USE ONLY. The product may not be used for other purposes.